RU-SKI 43 Hcl is a small molecule inhibitor of Hhat(Hedgehog acyltransferase), the enzyme responsible for the attachment of palmitate onto Shh.

Rufloxacin is a fluoroquinolone antibiotic.

RU-A1 is a novel potent BMI1 inhibitor that targets cellular self-renewal in hepatocellular carcinoma (HCC).

RU-505 is an effective inhibitor of the Aβ42-fibrinogen interaction with IC50 of 2.72 uM in FP assays.

RTC-5 is a dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 12.6 uM against H1650 lung adenocarcinoma cells.

RTC-30 is an orally active, dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 15 uM against H1650 lung adenocarcinoma cells.

RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.

RSV604 racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.

RSV604 R enantiomer is the R-enantiomer of RSV604, which is a potent respiratory syncytial virus (RSV) inhibitor targeting the nucleocapsid protein, is less active against RSV..

RSV inhibitor compound 1 is a novel potent, orally bioavailable RSV fusion inhibitor with EC50 of 2 nM (RSV Long strain infected HEp-2 cells) without significant cytotoxicity (CC50>100 uM).

RSK2-IN-20 is a potent, selective, and durable inhibitpr of RSK2 with IC50 of 47 nM.

RS 17053 hydrochloride is a potent and selective α1A adrenoceptor antagonist, with a pKi value of 9.1 in native cell membrane and a pA2 value of 9.8 in functional assays.

RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

RPR260243 was the first reported hERG channel activator.

Rpn11 inhibitor 35 is a potent, small molecule inhibitor of the proteasome subunit Rpn11 with IC50 of 400 nM,100-fold selectivity over Csn5 and 10-fold selectivity over AMSH.

RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.

RP-1865 is a selective stimulator of S1P1 and S1P5 used for the treatment of autoimmunity disease.

RP-1859 is a selective stimulator of S1P1 and S1P5 (S1P1 IC50 = 0.20 nM; S1P5 IC50 = 170 nM) used for the treatment of autoimmunity disease.

Roy-Bz is the first small-molecule PKCδ-selective activator with EC50 of 58.5 nM, binds to the PKCδ-C1-domain.

Roxyl-WL is a highly potent and selective inhibitor of IDO1 with IC50 of 1 nM.

Rotigotine is dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Rotigotine also has significant affinity for 5-HT1A and adrenergic α2B receptors. Rotigotine exhibits antiparkinsonian acitivity.

RORγt inverse agonist 32 is a potent, orally bioavailable inverse agonist of RORγt with IC50 of 9 nM in SPA binding assays.

RORγt inverse agonist 22 is a potent, subtype selective RORγt inverse agonist with binding IC50 of 18 nM, displays >192-fold selectivity over RORα and RORβ.

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

ROMK-IN-32 is a potent, selective ROMK inhibitor with IC50 of 17 nM.

ROMK-IN-25 is a potent and selective ROMK channel (KCNJ1) inhibitor with IC50 of 72 nM.

Robotnikinin is asmall molecule that binds the extracellular Sonic Hedgehog (Shh) protein (Kd=3.1 uM) and blocks Shh-signaling in cell lines, human primary keratinocytes and synthetic model of human skin.

RO-7 is a novel small molecule, broad-spectrum inhibitor of influenza acidic polymerase (PA) protein endonuclease activity with EC50 of 3.2-16 nM in MDCK cells.

RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure..